During the past decade, Centro Unico Regionale Trapianti di Midollo Osseo - Ospedale Bianchi-Melacino-Morelli conducted 7 clinical trials. In the 10-year time frame, 7 clinical trials started and 0 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 3 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

In terms of collaborators to trials, out of the total clinical trials conducted in "Centro Unico Regionale Trapianti di Midollo Osseo - Ospedale Bianchi-Melacino-Morelli" #1 collaborator was "Azienda Policlinico Umberto I" with 2 trials as a collaborator, "Associazione Italiana di Immunogenetica e Biologia dei Trapianti (AIBT)" with 1 trials as a collaborator, "Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia" with 1 trials as a collaborator, "National Marrow Donor Program" with 1 trials as a collaborator and "University of Rome Tor Vergata" with 1 trials as a collaborator. Other collaborators include -5 different institutions and companies that were collaborators in the rest 5 trials.

According to Clinical.Site data, the most researched conditions in "Centro Unico Regionale Trapianti di Midollo Osseo - Ospedale Bianchi-Melacino-Morelli" are "Hematologic Diseases" (4 trials), "Stem Cell Transplant Complications" (3 trials), "Myelofibrosis" (2 trials), "Acute Myeloblastic Leukemia" (1 trials) and "Chronic Graft Versus Host Disease" (1 trials). Many other conditions were trialed in "Centro Unico Regionale Trapianti di Midollo Osseo - Ospedale Bianchi-Melacino-Morelli" in a lesser frequency.

Most popular intervention types in "Centro Unico Regionale Trapianti di Midollo Osseo - Ospedale Bianchi-Melacino-Morelli" are "Drug" (4 trials). Other intervention types were less common.

The name of intervention was led by "A: Fludarabine + Busulphan" (1 trials), "Alentuzumab" (1 trials), "B: Fludarabine + Thiotepa" (1 trials), "Globulina antilinfocitaria" (1 trials) and "GvHD prophylaxis" (1 trials). Other intervention names were less common.

The vast majority of trials in "Centro Unico Regionale Trapianti di Midollo Osseo - Ospedale Bianchi-Melacino-Morelli" are 10 trials for "All" genders.

Currently, there are NaN active trials in "Centro Unico Regionale Trapianti di Midollo Osseo - Ospedale Bianchi-Melacino-Morelli". undefined are not yet recruiting, undefined are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 10 completed trials in Centro Unico Regionale Trapianti di Midollo Osseo - Ospedale Bianchi-Melacino-Morelli, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Centro Unico Regionale Trapianti di Midollo Osseo - Ospedale Bianchi-Melacino-Morelli, 1 "Phase 1" clinical trials were conducted, 3 "Phase 2" clinical trials and 1 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".